Rotator cuff repair: challenges and solutions

Abstract: Each year, 250,000 rotator cuff repairs are performed in the United States at a cost of $3 billion. Despite advancements in repair techniques and rehabilitation, 20%–70% of repairs continue to undergo structural failure; however, there is a poor correlation between clinical and structural outcomes, both before and after surgery. “Failure in continuity”, or retraction of the repair site without a structural defect, is likely a common phenomenon after rotator cuff repair, and this retraction of the myotendinous unit and interposing scar tissue may be one explanation for the discordance between clinical and structural outcomes. Scaffolds, both synthetic and biologic, have shown promise in both augmentation of repairs and interposition of irreparable tears, but most studies are small retrospective case series without control groups. Future efforts will need to determine the ideal indications for use, methods of application, and comparative effectiveness between the devices. Platelet-rich plasma also has potential to improve rotator cuff healing, but current limitations include the significant variation in preparation methods, biologic makeup, and application methods. Future work may help us understand whether application of platelet-rich plasma and its growth factors should be done at the time of surgery or later during a more advanced stage of healing. Regardless of the device or technique, mechanical and/or biologic augmentation of rotator cuff repairs requires the surgeon to be technically proficient in its use and aware of its associated increased operative time and cost. In order to justify the use of these technologies and their associated incremental cost, we must demonstrate efficacy in improving both clinical and structural outcomes.

Keywords: rotator cuff, repair, tear, augmentation, scaffold, biologic, PRP

Introduction
Rotator cuff tears (RCT) are the number one cause of shoulder disability in patients older than 65 years of age and affect 40% of the population older than 60 years of age. In the United States alone, 250,000 patients undergo rotator cuff repair (RCR) annually, at an estimated cost of $3 billion. Reports on structural outcomes using advanced imaging such as ultrasound (US) or magnetic resonance imaging (MRI) show that 20%–70% of RCRs fail by retearing, despite advances in surgical techniques and postoperative rehabilitation. Many studies suggest that patients with structurally intact repairs have better patient-reported outcomes (PROs), range of motion, and strength than those with structural retears, although a recent meta-analysis demonstrated that these differences are too small to be clinically meaningful. Furthermore, patients with structurally intact repairs can present with persistent weakness and dysfunction that would imply a failed repair, while patients with structurally failed repairs often show improved clinical outcomes in pain and...
function that would imply a healed repair.10–33 These weak correlations between structural integrity and measurable clinical outcomes limit investigative efforts and advances in the diagnosis and treatment of patients with RCTs. Here, we examine current definitions of rotator cuff “healing” and explore current solutions to reduce retear rates by mechanical and biological augmentation of the repair site.

What is “healing”? In 1991, Harryman et al16 brought attention to structural healing of repairs of the rotator cuff when they evaluated structural integrity by US and correlated this with functional results. The authors used US to characterize initial and recurrent tear size as type 0 for intact tendons, type 1A for partial thickness tears, type 1B for full thickness tears of the supraspinatus, type 2 for tears of the supraspinatus and infraspinatus, and type 3 for tears of the supraspinatus, infraspinatus, and subscapularis. They noted that patients with healed tendons had better function and less pain than those with recurrent defects and that 80% of type 1B tears healed compared to 57% of type 2 tears and 32% of type 3 tears. In addition to initial tear size, older age and revision surgery were correlated with repair failure.

In 2005, Sugaya et al34 expanded the definition of structural integrity in their study that used MRI to evaluate single- and double-row repairs, and this classification has been used widely since. Assessed on postoperative T2-weighted images, type I indicates sufficient thickness with homogeneously low intensity on each image, type II indicates sufficient thickness with a partial high-intensity area, type III indicates insufficient thickness without discontinuity, type IV indicates the presence of a minor discontinuity in more than one slice on each image suggesting a small tear, and type V indicates the presence of a major discontinuity on each image suggesting a medium or large tear. A follow-up study from the same group revealed that patients with larger recurrent defects, specifically those with type V repairs, had worse outcomes.22

However, patients with structurally intact repairs can present with persistent weakness and dysfunction that would imply a failed repair,22–29 despite a lack of imaging evidence to support a failure. One explanation may be that the repair has undergone “failure with continuity”, defined as failure of the initial surgical construct by any means, including elongation of the muscle–tendon unit, without a full-thickness anatomic defect. Although imaging reveals an anatomically intact tendon, at least some portion of the tissue connecting the rotator cuff muscle to the bone is a tendon-like material that is of variable thickness, resulting in the myotendinous junction being medially displaced from its anatomic or initially repaired location. The lack of restoration of the normal length and location of the myotendinous unit associated with the presence of tissue has the same functional effect of a failed repair with a recurrent full thickness tissue defect (Figure 1).

Evidence for “failure with continuity” following RCR has been shown in two recent studies.35,36 Baring et al35 used metal suture markers to measure tendon retraction in ten patients after RCR. They noted that tendon retraction occurs during the second and third postoperative months when patients undergo the most intense physical therapy. Mean tendon retraction was 7.0 mm, and nine of ten patients underwent retraction of 4.0 mm or more.

Similarly, McCarron et al36 analyzed repair site elongation in a prospective cohort of 14 patients, with full-thickness RCT treated with a SutureBridge repair construct and a standardized postoperative rehabilitation protocol. Retraction was measured on serial computed tomography (CT) scans using tantalum beads placed within the rotator cuff tendons at the time of repair, and structural integrity was measured on serial MRIs. Both CT and MRI were performed at 6, 12, 26, and 52 weeks postoperatively to correlate retraction and defect formation. All patients underwent retraction of the repaired tendon, while only 30% had a recurrent defect at final follow-up. Mean retraction at 52 weeks was similar in those with structurally intact repairs compared to those with recurrent defects, 15.2 vs 18.3 mm. In addition, 80% of the tendon retraction after RCR occurred in the first 12 weeks, suggesting that repair failures – with or without a recurrent defect – occur early in the postoperative period.36 This conclusion is supported by Miller et al37 who showed that seven of nine retears occurred within 3 months of repair, while the other two occurred between 3 and 6 months. Similarly, Iannotti et al38 found that 8 of 19 structural failures of RCR occurred between 0 and 12 weeks after repair and 10 of 19 occurred between 12 and 26 weeks, and Hernigou et al39 found that 7 of 15 structural failures seen in the first 6 months were evident by 3 months.

These studies show that RCR failure occurs frequently, early, and with or without an anatomic full thickness tissue defect, and together suggest the need for strategies to augment the repair construct. It is likely that failures that occur in the first 4–6 weeks represent an inability of the surgical construct to mechanically maintain the integrity of the repair site. During this acute and subacute postoperative period of hemostasis and inflammation, biologic factors likely play little
role in the healing process and probably contribute little to the strength of the repair. Mechanical augmentation, in the form of a scaffold, may be able to minimize these early, mechanical failures. In contrast, later failures, particularly those in the 3–6 months period as the patient stresses the repair site while working to regain motion and strength, likely represent a biologic failure to heal. Biologic augmentation, in the form of platelet-rich plasma (PRP) or cell seeding, may offer a means to improve the quality or rate of healing. Further, a scaffold may offer a means to deliver these biologic therapies, as well as mechanically protect and stabilize the healing repair construct to facilitate their activity. Better understanding of biologic tendon healing and the timeline of the reparative process that occurs after surgery will serve to guide our efforts to mechanically and biologically augment RCRs.

**Solutions**

Given the large number of RCRs performed annually and the high rate of structural failure, there is a need to augment the repair site by mechanically reinforcing it and by biologically enhancing the rate and quality of the healing process. Current techniques available for use in clinical practice include the application of scaffolds, both biologic and synthetic, and the use of PRP.

**Scaffolds**

Scaffold devices for augmentation of RCR exist in the form of extracellular matrix (ECM) and synthetic polymers. Both ECM and synthetic scaffolds work to mechanically off-load the repair site at time-zero and during the initial period of host healing after repair. ECM scaffolds also provide a chemically and structurally instructive setting to biologically influence the rate and quality of tendon healing. Nonhuman-derived ECM and synthetic devices must undergo the 510(k) regulatory process of the US Food and Drug Administration (FDA) for marketing as medical devices. Clearance does not require proof of efficacy but, rather, requires proof of equivalence to other devices in performance, biocompatibility, safety, stability, sterility, and packaging. In contrast, human-derived ECM scaffolds are considered human tissue for transplantation and require no clearance from the FDA if minimally manipulated and used homologously.
Immune responses to scaffolds

ECM scaffolds induce histologic and morphologic responses in the host depending on species and tissue of origin, processing, terminal sterilization, and the loading environment. Porcine small intestine submucosa (SIS) scaffolds elicit a macrophage immune response. Cross-linked scaffolds elicit giant cells, chronic inflammation, and poorly organized fibrous tissue. The immune response to other ECM devices is less defined, as some may undergo slower remodeling and some degree of incorporation with host tissue. Synthetic scaffolds elicit responses depending on the material composition and morphology, including size, shape, porosity, and roughness. A more in-depth discussion of the host immune response to ECM scaffolds can be found in prior reviews on this subject.

Cadaveric studies on scaffolds

The degree to which a scaffold can mechanically augment the repair site depends on the material, geometry, and suture retention properties. Variables that the surgeon controls include the number, type, and location of sutures, and the pretensioning of the graft at the time of fixation. The mechanical augmentation will diminish as the scaffold degrades during the healing period, though this would ideally occur at the same time or later than healing of the host tissue and remodeling of the graft. McCarron et al evaluated poly-L-lactide grafts for augmentation of repairs in human cadaver shoulders. Yield load and ultimate load were significantly improved compared to nonaugmented repairs, and 7 of 20 augmented repairs failed at the suture–tendon interface compared to 17 of 20 nonaugmented repairs. Barber et al also demonstrated improved time-zero failure load in a human cadaveric model of RCR using human dermal allograft compared to standard RCR. They noted that failure strengths improved from 273±116 N for nonaugmented repairs to 325±74 N for augmented repairs, and 6 of 10 augmented repairs failed at the suture–tendon interface compared to 8 of 10 nonaugmented repairs. In another human cadaver study, McCarron et al demonstrated improved mechanical properties of augmentation with a fascia lata patch reinforced with poly-L-lactic acid. Gap formation after 1,000 cycles was 4.7 mm in augmented repairs compared to 7.3 mm in nonaugmented repairs, and all augmented repairs were intact at 1,000 cycles compared to only 6 of 9 nonaugmented repairs. Together, these studies demonstrate the potential for graft augmentation to improve the mechanical properties of the rotator cuff tendon repair, at least at the time of surgery.

Importantly, Sahoo et al showed that acellular human dermis grafts underwent significant and unrecoverable elongation at low physiologic loads. The study also showed that preconditioning the grafts by cyclical stretching, use of reverse cutting needles for suture fixation, and application of about 20 N of pretensioning at the time of application in situ reduced the compliance of the graft. This information reinforces the importance of the method of application of the graft on its performance in augmenting the repair site.

Clinical studies on scaffolds

Although the FDA has approved scaffolds for use in augmentation of completed repairs, there is a relatively even split in the number of series using grafts to augment fully repairable tears compared to using grafts as interposition devices in partial repairs or irreparable tears. Most clinical series with the use of scaffolds in RCR are retrospective case series without control groups, include small sample sizes, and have relatively short-term follow-up. Through a systematic review of the MEDLINE database and associated bibliographies, we identified all clinical series reporting on the use of commercially available scaffolds for augmentation or interposition of RCR as of March 2015, and these are reviewed below.

The first clinical series of ECM scaffolds included a noncross-linked porcine SIS, Restore Orthobiologic Implant (DePuy, Warsaw, IN, USA). Two studies, including a prospective randomized trial from our institution, revealed a severe, aseptic, postoperative inflammatory reaction in 20%–30% of patients receiving the device, in addition to no benefit in functional or structural outcomes. As a result, the American Academy of Orthopaedic Surgeons (AAOS) recommends against the use of noncross-linked porcine SIS grafts.

Two retrospective case series on a cross-linked dermis scaffold, Zimmer Collagen Repair (Zimmer, Warsaw, IN, USA), reported mixed results, with one noting good functional results and structural integrity and another noting a high rate of graft disruption and aseptic inflammatory reactions. Several retrospective case series using noncross-linked human dermis scaffolds, such as GraftJacket (Wright Medical, Arlington, TX, USA), demonstrate improved patient outcomes when used for either augmentation or interposition. A recent prospective randomized controlled trial compared augmentation of chronic two-tendon tears with noncross-linked human dermis to standard repair without augmentation. Functional scores, as assessed by the American Shoulder and Elbow Surgeons (ASES) Score...
<table>
<thead>
<tr>
<th>Device</th>
<th>Reference (year)</th>
<th>Study design (level of evidence)</th>
<th>Tear size</th>
<th>Sample size</th>
<th>Method of application</th>
<th>Follow-up (months)</th>
<th>Structural failure</th>
<th>Functional outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>GraftJacket® (human dermis)</td>
<td>Burkhart et al (2007)</td>
<td>IV (retrospective case series)</td>
<td>Massive</td>
<td>17</td>
<td>Open</td>
<td>14</td>
<td>3/12</td>
<td>UCLA: 9.06→26.12</td>
<td>No adverse events reported. Scores, strength, ROM improved; 14/17 patients satisfied with outcome. Recurrent tears were smaller than on pre-operative MRI.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II (prospective randomized controlled trial)</td>
<td>Two-tendon (&gt;3 cm)</td>
<td>NA: 20</td>
<td>Arthroscopic</td>
<td>12–38 months</td>
<td>NA: 9/15 A: 3/20</td>
<td>UCLA: NA 28.3, A 28.2 Constant: NA 85.3, A 91.9 ASES: NA 85.3, A 98.9</td>
<td>No adverse events reported. Augmented group had significantly better Constant and ASES scores, and significantly better healing rate by MR arthrogram, compared to nonaugmented group.</td>
</tr>
<tr>
<td>X-Repair® (poly-L-lactide)</td>
<td>Proctor (2014)</td>
<td>IV (retrospective case series)</td>
<td>Large or massive</td>
<td>18</td>
<td>Arthroscopic</td>
<td>35–47 months</td>
<td>4/18</td>
<td>AS: 26→70</td>
<td>No adverse events reported. Mean ASES score for intact repairs =82.</td>
</tr>
<tr>
<td></td>
<td>Lenart et al (2014)</td>
<td>IV (retrospective case series)</td>
<td>Massive</td>
<td>13</td>
<td>Open</td>
<td>14–20 months</td>
<td>8/13</td>
<td>ASES: 32.8→74.2 FLEX: 53.7→79.7 Constant: 49.7→81.1</td>
<td>No adverse events reported. Significant improvement in functional outcomes despite high rate of structural failure.</td>
</tr>
<tr>
<td>Allopatch HD™ (human dermis)</td>
<td>Agrawal (2012)</td>
<td>IV (retrospective case series)</td>
<td>Large, massive, or recurrent</td>
<td>14</td>
<td>Arthroscopic</td>
<td>14–19 months</td>
<td>2/14</td>
<td>ASES: 64→88</td>
<td>No adverse events reported. Healed repairs showed graft incorporation into native tissue on MRI.</td>
</tr>
<tr>
<td>Acellular Human Dermal Matrix (human dermis)</td>
<td>Rotini et al (2011)</td>
<td>IV (retrospective case series)</td>
<td>Large or massive</td>
<td>5</td>
<td>Arthroscopic (2/5 or open (3/5))</td>
<td>12–18 months</td>
<td>2/5</td>
<td>Constant: 49.7→81.1</td>
<td>No adverse events reported. Scores, pain, strength, ROM improved. Recurrent tears were smaller than on preoperative size.</td>
</tr>
<tr>
<td>Zimmer® Collagen Repair (porcine dermis)</td>
<td>Cho et al (2014)</td>
<td>IV (retrospective case series)</td>
<td>Massive</td>
<td>5</td>
<td>Mini-open</td>
<td>14–27 months</td>
<td>1/5</td>
<td>UCLA: 15.4→31.2 ASES: 39.4→86.4</td>
<td>No adverse events reported. Scores and pain improved. There was 1 partial retear.</td>
</tr>
<tr>
<td>Repol Angimesh® (RA) (polypropylene)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Smaller tears (single tendon tears of supraspinatus or infraspinatus). No adverse events reported. Scores, pain, ROM improved.</td>
</tr>
<tr>
<td>Biomix RCR Patch™ (polycarbonate polyurethane)</td>
<td>Encalada-Diaz et al (2011)</td>
<td>IV (retrospective case series)</td>
<td>Small, medium (mean 2 cm)</td>
<td>10</td>
<td>Open</td>
<td>12 months</td>
<td>11/10</td>
<td>AS: 44→73</td>
<td>No adverse events reported. Scores, pain, strength improved. 6 excellent, 2 good, 2 fair results by DASH.</td>
</tr>
<tr>
<td>SportMesh™ (polyurethaneurea)</td>
<td>Petriccioni et al (2013)</td>
<td>IV (retrospective case series)</td>
<td>Two-thirds to complete subscapularis tears</td>
<td>10</td>
<td>Open</td>
<td>12–34 months</td>
<td>1/10</td>
<td>Constant: 47→69</td>
<td>No adverse events reported. Scores, pain, strength improved. 6 excellent, 2 good, 2 fair results by DASH.</td>
</tr>
</tbody>
</table>

**Notes:** Most clinical studies are retrospective case series without control groups that demonstrate improved patient outcomes over the preoperative state and relatively low rates of structural failure. Adverse events with these currently available scaffolds are rare. *Not all patients underwent imaging for evaluation of structural failure.* The arrows in the functional outcomes column denote change from pre- to postoperative values.

**Abbreviations:** A: augmented; ASES, American Shoulder and Elbow Surgeons Shoulder Score; DASH, Disabilities of the Arm, Shoulder, and Hand Outcome Measure; Flex SF, Flex Level of Shoulder Function; MRI, magnetic resonance imaging; NA, nonaugmented; Penn, Penn Shoulder Score; ROM, range of motion; SST, Simple Shoulder Test; UCLA, University of California, Los Angeles Shoulder Score.
Table 2 Studies of commercially available scaffolds in interposition of irreparable rotator cuff tears

<table>
<thead>
<tr>
<th>Device</th>
<th>Reference (year)</th>
<th>Study design (level of evidence)</th>
<th>Tear size</th>
<th>Sample size</th>
<th>Method of application</th>
<th>Follow-up</th>
<th>Structural failure</th>
<th>Functional outcomes†</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>GraftJacket® (human dermis)</td>
<td>Dopirak et al (2007)¹⁰</td>
<td>IV (retrospective case series)</td>
<td>Massive, irreparable</td>
<td>16</td>
<td>Arthroscopic</td>
<td>12–38 months</td>
<td>3/16</td>
<td>UCLA: 18.4 → 30.4 Constant: 53.8 → 84</td>
<td>No adverse events reported. Scores, pain, strength, ROM improved; 15/16 patients satisfied with outcome. Thirteen patients had full incorporation of graft into native tissue on MRI.</td>
</tr>
<tr>
<td></td>
<td>Bond et al (2008)¹⁰</td>
<td>IV (retrospective case series)</td>
<td>Massive, irreparable</td>
<td>45</td>
<td>Arthroscopic</td>
<td>24–68 months</td>
<td>n/a</td>
<td>UCLA: 18.4 → 27.5 WORC: 75.2 ASES: 84.1</td>
<td>No adverse events reported. Scores, pain, strength, ROM improved; and all patients satisfied with outcome. There were no complete retears, only partial retears.</td>
</tr>
<tr>
<td></td>
<td>Wong et al (2010)¹⁰ (update from Bond et al 2008)</td>
<td>IV (retrospective case series)</td>
<td>Massive, irreparable</td>
<td>24</td>
<td>Mini-open</td>
<td>29–42 months</td>
<td>5/19</td>
<td>SF-12: 48.8 → 56.8 ASES: 66.6 → 88.7</td>
<td>No adverse events reported. Scores, pain, strength, ROM improved; and all patients satisfied with outcome. There were no complete retears, only partial retears.</td>
</tr>
<tr>
<td></td>
<td>Gupta et al (2012)¹⁰</td>
<td>IV (retrospective case series)</td>
<td>Massive, irreparable</td>
<td>24</td>
<td>Arthroscopic, superior capsule reconstruction</td>
<td>24–51 months</td>
<td>4/24</td>
<td>ASES: 23.5 → 92.9</td>
<td>No adverse events. Graft used to recreate superior capsule from superior glenoid to greater tuberosity. Improved motion and functional outcomes, with high rate of structural integrity.</td>
</tr>
<tr>
<td></td>
<td>Mihata et al (2013)¹⁰</td>
<td>IV (retrospective case series)</td>
<td>Large, or massive, irreparable</td>
<td>24</td>
<td>Arthroscopic</td>
<td>35 months</td>
<td>FL: 2/24</td>
<td>FL: 40.8 → 90.1 PR: 41.8 → 85.7 Constant: FL: 37.4 → 81.1 PR: 36.3 → 69.9 UCLA: FL: 14.3 → 32.6 PR: 13.7 → 29.8</td>
<td>No adverse events. Fascia lata autograft resulted in improved structural and functional outcomes compared to partial repair of irreparable large or massive rotator cuff tears.</td>
</tr>
<tr>
<td></td>
<td>Mori et al (2013)¹⁰</td>
<td>III (retrospective comparative study)</td>
<td>Large, or massive, irreparable</td>
<td>FL: 24 PR: 24</td>
<td>Arthroscopic</td>
<td>35 months</td>
<td>FL: 2/24</td>
<td>ASES: FL: 40.8 → 90.1 PR: 41.8 → 85.7 Constant: FL: 37.4 → 81.1 PR: 36.3 → 69.9 UCLA: FL: 14.3 → 32.6 PR: 13.7 → 29.8</td>
<td>No adverse events. Graft disruption occurred between 3 and 6 months postoperatively in all patients. Inflammatory reaction seen in all patients, with graft disintegration and tissue necrosis observed at revision surgery.</td>
</tr>
<tr>
<td></td>
<td>Zierer et al (2007)¹¹</td>
<td>IV (retrospective case series)</td>
<td>Massive</td>
<td>4</td>
<td>Open</td>
<td>3–6 months</td>
<td>4/4</td>
<td>n/a</td>
<td>Older patient population (71–82 years). Graft disruption occurred between 3 and 6 months postoperatively in all patients. Inflammatory reaction seen in all patients, with graft disintegration and tissue necrosis observed at revision surgery.</td>
</tr>
<tr>
<td></td>
<td>Soler et al (2007)¹¹</td>
<td>IV (retrospective case series)</td>
<td>Large or massive</td>
<td>10</td>
<td>Open</td>
<td>3–5 years</td>
<td>2/10</td>
<td>Constant: 42 → 62</td>
<td>No adverse events reported. Scores, pain, ROM, abduction power improved; 9/10 patients satisfied with outcome.</td>
</tr>
</tbody>
</table>

† Scores: UCLA, Constant, ASES, WORC, ASeS.
and the Constant Shoulder Score, were significantly better in the augmented group, and MRI evaluation at 1–2 years demonstrated significantly higher rate of healed repairs in the augmented group, 85% compared to 40%. There were no adverse events noted.

Several synthetic grafts have been examined in retrospective case series, and similar to other devices, patients experienced improved clinical outcomes and a low rate of structural failure. One study comparing augmentation with a polypropylene mesh, Repol Angimesh (Angiologica, Pavia, Italy), to bovine pericardium, Tutopatch (Med&Care, Gdynia, Poland), and to nonaugmented repairs demonstrated better outcomes and less structural failures (17%, 51%, and 41%, respectively) with the synthetic mesh.58

Many available scaffolds have never been evaluated in the peer-reviewed literature, and many of the studies that do exist are case series with small sample sizes and no control groups of standard, nonaugmented repairs. These studies include a wide range of devices (allografts, xenografts, and synthetic grafts) indications (augmentation for irreparable tears, or interposition for irreparable tears), and outcomes (various functional outcome tools, different imaging modalities to evaluate structural integrity). Higher quality studies are needed to elucidate what size tears benefit from augmentation or interposition, open or arthroscopic application, and which devices improve structural and functional outcomes with a minimal risk profile.

PRP preparation and mechanism of action

Because platelets are naturally involved in hemostasis and thrombosis during the early inflammatory phase of healing, and because platelets house many growth factors believed to be responsible for the healing process and reintroducing them to the site of injury, PRP is used to enhance recruitment, proliferation, and differentiation of regenerative cells in tissue repair.67

PRP has been used to biologically augment healing after injury and repair in other areas of dentistry, maxillofacial surgery, plastic surgery, and orthopedic surgery.63–66 By concentrating the growth factors believed to be responsible for the healing process and reintroducing them to the site of injury, PRP is used to enhance recruitment, proliferation, and differentiation of regenerative cells in tissue repair.67

Conexa™ (porcine dermis) Gupta et al (2013)IV (retrospective case series) Massive, irreparable 27 Mini-open 24–40 months 6/22 SF-12: 48.4→56.6 ASES: 62.7→91.8 No adverse events reported. Scores, pain, strength, ROM improved. All but one patient satisfied with outcome. There was one complete retear and five partial retears.

LARS graft (polyester terephthalate) Petrie and Ismaiel (2013)IV (retrospective case series) Massive, irreparable 31 Open 24–72 months n/a Oxford: 46.7→30.6 No adverse events reported. Graft not always secured medially to retracted tear stump. Lower Oxford score is better. Scores and pain improved. Two revisions with graft failure noted, but other cases not imaged postoperatively for healing.

Notes: Most clinical studies are retrospective case series without control groups that demonstrate improved patient outcomes over the preoperative state and relatively low rates of structural failure. Adverse events with these currently available scaffolds are rare. Not all patients underwent imaging for evaluation of structural failure. The arrows in the functional outcomes column denote change from pre- to postoperative values.

Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; FL, fascia lata; LARS, ligament advanced reinforcement system; MRI, magnetic resonance image; n/a, not applicable; Oxford, Oxford Shoulder Score; PR, partial repair; ROM, range of motion; SF-12, 12-Item Short Form Health Survey; UCLA, University of California, Los Angeles Shoulder Score; WORC, Western Ontario Rotator Cuff Index.

Orthopedic Research and Reviews downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Apr-2018

For personal use only.
growth factor-1) are among those known to play a role in cell proliferation and differentiation, chemotaxis, angiogenesis, and ECM production, and they can be expected to influence tendon healing.67,69–71

PRP is an autologous blood concentrate that contains at least 1 million platelets per microliter, 4–7 times that of whole blood.72 However, the amount of growth factors present varies significantly between formulations, between individuals, and even between samples taken from the same individual. Even when using the same preparation method and the same patient’s blood, the end product is highly variable in its platelet and leukocyte concentration. In fact, a patient’s platelets may fail to concentrate with one preparation system but successfully concentrate with another.68,73

A recent qualitative classification system allows comparison between preparations and proposes consistent terminology.74 Three factors, leukocyte content, exogenous platelet activation, and the presence of a strong fibrin architecture, define the six categories. Leukocytes in the product signify the presence of inflammatory cytokines and matrix metalloproteinases, in addition to the growth factors from the platelets.68 Exogenous activation typically involves combining the concentrate with calcium chloride or thrombin immediately before administration to initiate platelet activation, clot formation, and the release of growth factors from α granules.72 Typical formulations release 70% of their growth factors within 10 minutes and 100% within 1 hour.75 A strong fibrin architecture, in the form of a platelet-rich fibrin (PRF) matrix, allows delayed growth factor release over 5–7 days. A second centrifugation in the presence of calcium chloride leads to the formation of the PRF matrix.72 Understanding how these three factors affect the end product will allow clinicians and scientists to better understand the effect of different PRP products on the healing process.

Clinical studies on PRP use in RCR
In contrast to the literature on scaffolds in augmentation of RCR, high-quality evidence on the use of PRP in RCR exists, albeit all have small sample sizes and only a few preparation methods have been investigated. Eight prospective randomized trials have compared RCR augmented with PRP to standard RCR (Table 3).76–83

Three prospective randomized trials utilized a PRF matrix from the Cascade Medical FIBRINET system (Musculoskeletal Transplant Foundation, Edison, NJ, USA) and interposed it at the tendon–bone interface during arthroscopic RCR. All studies demonstrated no difference in structural integrity. Regarding functional outcomes at final follow-up, Castricini et al76 and Rodeo et al80 showed no difference, while Weber et al82 showed worse University of California Los Angeles (UCLA) scores. Two retrospective studies did demonstrate differences in structural healing, one demonstrating less failures,84 with another demonstrating more failures.85

Similarly, Gumina et al77 used a platelet-leukocyte membrane (PLM) from the RegenKit system (Regen Lab, Le Mont-Lausanne, Switzerland) in a prospective randomized trial. They demonstrated a lower rate of structural failure in the PLM group, but no difference in functional outcomes.

The use of two other products, a PRP product from the Gravitational Platelet Separation (GPS) II (Biomet, Warsaw, IN, USA) and a PRP gel from the COBE Spectra LRS Turbo (CaridianBCT, Lakewood, CO, USA), has resulted in a lower rate of structural failure in randomized trials; however, neither resulted in differences in functional outcomes.78,79 On the other hand, the use of fibrin-rich PRP from the Vivostat PRF system (Vivostat A/S, Alleroed, Denmark) or plasma rich in growth factors from the PRGF System 1 (BTI Biotechnology Institute, Vitoria-Gasteiz, Spain) resulted in no differences in structural integrity or functional outcomes in randomized trials.81,83

An up-to-date meta-analysis of prospective randomized controlled trials of PRP in RCR demonstrated no differences in structural integrity or functional outcomes.86 Despite relatively high-quality studies, the meta-analysis included six different products, relatively small sample sizes, and short-term follow-up of around 1–3 years. Though in vitro studies suggest that PRP holds promise in tendon healing, clinical studies have failed to demonstrate improved outcomes. However, further in vitro and animal studies are needed to investigate methods of preparation, activation, and application before more widespread clinical investigation and use.

Summary and future directions
Despite a growing body of research and numerous FDA-cleared scaffold and PRP products intended to improve healing rates after RCR, limited evidence exists to support their efficacy, and wide-spread clinical adoption has not occurred to date. Mechanical and biologic augmentation strategies, including the emerging use of cell-based therapies,39,87 require additional surgical expertise and operative time. In order to justify reimbursement for these additional costs, we must prove that these efforts will lead to a substantial change in outcomes for our patients. The appropriate indications, optimal timing and technique of application, and best products must be determined, and our definition of rotator cuff...
Table 3  Level I and II studies on PRP use in rotator cuff repair

<table>
<thead>
<tr>
<th>PRP product</th>
<th>Device</th>
<th>Reference</th>
<th>Study design (level of evidence)</th>
<th>Tear size</th>
<th>Sample size (PRP:control)</th>
<th>Follow-up</th>
<th>Structural failure*</th>
<th>Functional outcomes†</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet-Rich Fibrin Matrix</td>
<td>Cascade Autologous Platelet System</td>
<td>Castricini et al (2011)</td>
<td>I (randomized controlled trial)</td>
<td>Small or medium</td>
<td>43:45</td>
<td>16 months</td>
<td>PRFM: 1/43 C: 4/45</td>
<td>Constant: PRFM: 42.0→88.4 C: 42.9→88.4</td>
<td>No adverse events. Improved tendon signal in PRFM group. No differences in strength, constant scores, or structural failure. No adverse events. No differences in functional scores, structural integrity, or strength at final follow-up, but PRFM group was 5.8 times more likely to have recurrent defect. No adverse events. No differences in early pain scores, or final functional scores or structural integrity.</td>
</tr>
<tr>
<td></td>
<td>(Musculoskeletal Transplant Foundation, Edison, NJ)</td>
<td>Rodeo et al (2012)</td>
<td>II (randomized controlled trial)</td>
<td>Small, medium, or large</td>
<td>40:39</td>
<td>12 months</td>
<td>PRFM: 12:36 C: 6/31</td>
<td>ASES: PRFM: 56.2→91.3 C: 54.7→96.4 L'insalata: PRFM: 50.6→90.4 C: 50.6→94.1</td>
<td>No adverse events. Improved tendon signal in PRFM group. No differences in strength, constant scores, or structural failure. No adverse events. No differences in functional scores, structural integrity, or strength at final follow-up, but PRFM group was 5.8 times more likely to have recurrent defect. No adverse events. No differences in early pain scores, or final functional scores or structural integrity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weber et al (2013)</td>
<td>I (randomized controlled trial)</td>
<td>Any (mean 1.7 cm)</td>
<td>29:30</td>
<td>12 months</td>
<td>PRFM: 12:28 C: 7/24</td>
<td>ASES: PRFM: 82.5 C: 82.5 UCLA: PRFM: 27.9 C: 29.6</td>
<td>No adverse events. Improved tendon signal in PRFM group. No differences in strength, constant scores, or structural failure. No adverse events. No differences in early pain scores, or final functional scores or structural integrity.</td>
</tr>
<tr>
<td>Plasma Gel</td>
<td>COBE Spectra LRS Turbo (Cardidan BCT, Lakewood, CO)</td>
<td>Jo et al (2011)</td>
<td>II (prospective cohort study)</td>
<td>Any (mean 2.6–3.5 cm)</td>
<td>20:18</td>
<td>12 months</td>
<td>PRPG: 4/15 C: 7/17</td>
<td>Equivalent Constant, ASES, UCLA, DASH, SST, SPADI scores</td>
<td>No adverse events. Improved tendon signal in PRFM group. No differences in strength, constant scores, or structural failure. No adverse events. No differences in early pain scores, or final functional scores or structural integrity.</td>
</tr>
<tr>
<td></td>
<td>GPS II – Plasmax – Platelet Concentration System (Bomet Biologics, Warsaw, IN)</td>
<td>Randelli et al (2011)</td>
<td>I (randomized controlled trial)</td>
<td>Any</td>
<td>22:23</td>
<td>24 months</td>
<td>PRP: 9/22 C: 12/23</td>
<td>Constant: PRP: 44→82.4 C: 42.2→78.7 UCLA: PRP: 15.3→33.3 C: 14.5→31.0 SST: PRP: 4.8→11.3 C: 4.7→10.9</td>
<td>No adverse events. Improved tendon signal in PRFM group. No differences in strength, constant scores, or structural failure. No adverse events. No differences in early pain scores, or final functional scores or structural integrity.</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>PRP product</th>
<th>Study design</th>
<th>Tear size</th>
<th>Study author</th>
<th>Follow-up</th>
<th>Functional outcomes</th>
<th>Structural failure</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma Rich in Fibrin (PRF)</td>
<td>Randomized controlled trial</td>
<td>Medium, large or massive</td>
<td>Ruiz-Moneo</td>
<td>12 months</td>
<td>UCLA: 14.9–23.2</td>
<td>PRGF: 14.8–23.8</td>
<td>No adverse events. No differences in structural integrity at final follow-up.</td>
</tr>
<tr>
<td>Plasma-Rich Fibrin (PRF)</td>
<td>Randomized controlled trial</td>
<td>Massive</td>
<td>Antuna</td>
<td>12 months</td>
<td>PRES: 39.7–65.6</td>
<td>C: 4.9–23</td>
<td>No adverse events. No differences in functional score at final follow-up.</td>
</tr>
</tbody>
</table>

Notes: Some studies suggest slightly better healing with PRF use, while others suggest no difference or even worse healing. Overall, there are no differences in structural integrity or functional outcomes with PRP use. Adverse events have not been reported. *Not all patients underwent imaging for evaluation of structural failure. The arrows in the functional outcomes column denote change from pre- to postoperative values.

Abbreviations: ASS, American Shoulder and Elbow Surgeons Shoulder Score; c-SCST, Constant Shoulder Score; C: control; DASH, Disabilities of the Arm, Shoulder, and Hand Outcome Measure; D: donor; DRC: Dutch Rotator Cuff; SPUT, Simple Shoulder Test; UCLA, University of California, Los Angeles Shoulder Score.

References


49. Del Fabbro M, Bortolin M, Taschieri S, Weinstein R. Is platelet concen...